|
PRELIMINARY PROGRAM |
Educational Objectives:
Upon completion of this workshop, participants should be able to:
- Describe current MRI/MRS methodologies used to diagnose cancer and
to evaluate response to therapies;
- Explain biostatistics for analyzing MR indices used in diagnosis and
therapeutic response monitoring;
- Evaluate different MRI contrast mechanisms and appropriately select
these for specific applications to cancer;
- Describe some of the unique metabolic/physiologic characteristics of
cancer that can be assessed by MRI/MRS;
- Explain the regulatory issues related to the introduction of new MRI
agents;
- Appraise the current role and expected future directions of MR in
the cancer research lab and the cancer clinic.
|
|
Friday, 18 October |
17:00-19:00 |
Registration
and Poster set-up |
17:30-21:00 |
Dinner |
Saturday, 19 October |
07:00-08:30 |
Breakfast/Registration |
08:30-08:40 |
Welcome
Michael Garwood, Ph.D., University of Minnesota, Minneapolis, MN, USA |
08:40-09:30 |
Importance of the Tumor Micro-Environment for Response to Therapy
J. Martin Brown, D.Phil., Stanford University, Stanford, CA, USA |
09:30-10:40 |
Contrast Enhanced MRI
Chair: Boudewijn van der Sanden, Ph.D., INSERM, CHU de Grenoble, Grenoble,
France
- 09:30 - 09:50: Introduction and Overview
Boudewijn van der Sanden, Ph.D., INSERM, CHU de Grenoble, Grenoble, France
- 09:50 - 10:10: "New Agents in the Pipeline"
Michael F. Tweedle, Ph.D., Bracco Research USA, Princeton, NJ, USA
- 10:10 - 10:40: Proffered Papers:
"Reproducibility of Dynamic Contrast enhanced MRI in Liver Metastasis of Colorectal
Cancer"
H. van Laarhoven, M.D., M.A., UMC Nijmegen, Nijmegen, Netherlands
"Simultaneous Measurement of Arterial Input Function and Tumor Perfusion in
Mice"
Rong Zhou, Ph.D., University of Pennsylvania, Philadelphia, PA, USA
"Contrast-Enhanced MR Guided Genomic and Proteomic Analysis of
Squamous Cell Carcinoma Tumor Model Based on Spatial and Temporal Changes"
Yi-Shan Yang, Stanford University School of Medicine, Stanford, CA, USA
|
10:40-11:00 |
Break |
11:00-12:00 |
Evaluating Anti-Angiogenic and Other Therapies by MRI
Chair: Ross J. Maxwell, Ph.D., Mount Vernon Hospital, Northwood, England, UK
- 11:00 - 11:20: Introduction and Overview
Ross J. Maxwell, Ph.D., Mount Vernon Hospital, Northwood, England, UK
- 11:20 - 11:40: "Encouraging clinical experience in monitoring
anti-angiogenic therapies by MRI"
Bruno Morgan, M.A., M.R.C.P., F.R.C.R., University of Leicester, Leicester, England, UK
- 11:40 - 12:00: Proffered Papers:
"Use of Paramagnetic Contrast Agents for In Vivo
Imaging of Tumor Oxygen Status"
Murali K. Cherukuri, Ph.D., National Cancer Institute, Bethesda, MD, USA
"BOLD-MRI Responses to Vasoactive Agents: Influence of Vessel
Maturity"
K.J. Lankester, Gray Cancer Institute, Mount Vernon Hospital, Northwood,
England, UK
|
12:00-13:30 |
Lunch |
13:30-14:15 |
“The Need for Better Imaging from an Oncologist’s
Perspective”
Douglas Yee, M.D., University of Minnesota Cancer Center, Minneapolis, MN, USA |
14:15-14:55 |
Poster Discussions:
- "BOLD MRI Response to Hypercapnic Hyperoxia in Patients with
Meningiomas: Correlation with Gadolinium-DTPA Uptake Rate"
M. Rijpkema, M.Sc., UMC Nijmegen, Nijmegen, Netherlands
- "Blood Volume and Vessel Size Imaging: Histological Validation
and Vasculature Characterization in Rat Brain During C6 Glioma Growth"
Laurent Lamalle, INSERM IFR 1, Grenoble, France
- "CPMG Measurements of USPIO-Induced DR2 in C26A Murine
Colon Carcinoma"
Giulio Gambarota, UMC Nijmegen, Nijmegen,
Netherlands
- "MR Imaging and Spectroscopy of Prostate Cancer with an
Endorectal Coil at 1.5 and 3 Tesla"
T.W.J. Scheenen, M.Sc., UMC Nijmegen, Nijmegen, Netherlands
- "Diffusion Tensor Imaging of the Prostate Following
Therapy"
Albert P. Chen, University of California, San Francisco, CA, USA
|
14:55-16:10 |
Poster session 1: Functional and Molecular Assessment of
Cancer |
16:10-16:30 |
Break |
16:30-17:50 |
Other MRI Contrasts in Cancer
Chair: Risto Kauppinen, M.D., Ph.D., University of Kuopio, Kuopio,
Finland
- 16:30-16:50: “T2* MRI”
Michal Neeman, Ph.D., Weizmann Institute of Science, Rehovot, USA
- 16:50-17:10: “T2 and T1p MRI”
Olli H.J., Gr�hn, Ph.D., Center for MR Research, Minneapolis, MN, USA
- 17:10-17:30: “Diffusion MRI”
Thomas L. Chenevert, Ph.D., University of Michigan, Ann Arbor, MI, USA
- 17:30-17:50: “Cell tracking by MRI”
Jeff W.M. Bulte, Ph.D., Johns Hopkins University, Baltimore, MD, USA
|
18:00-20:00 |
Dinner |
Sunday, 20 October |
07:00-09:00 |
Breakfast |
09:00-10:30 |
Special Negendank Session: Introduction and Overview of
Choline Metabolism: Membrane Turnover and/or Signal Transduction
Chair: Zaver M. Bhujwalla, Ph.D., Johns Hopkins University, Baltimore, MD, USA
- 9:00-9:15: Introduction and Overview
Zaver M. Bhujwalla, Ph.D., Johns Hopkins University, Baltimore, MD, USA
- 9:15-9:40: "Biochemistry of Choline Compounds"
Dennis E. Vance, Ph.D., F.R.S.C., University of Alberta, Edmonton, AL, Canada
- 9:40-10:10: "Cancer MR Studies of Choline Compounds - Basic
Research Perspective"
Sabrina M. Ronen, Ph.D., The Royal Marsden Hospital, Surrey, England, UK
- 10:10-10:30: Proffered Papers:
"Phosphocholine Response to Low Doses of Taxotere is Quantified and Correlated
with other Cellular Responses in Non-tumorigenic, Tumorigenic and Metastatic Breast Cancer
Cells"
David L. Morse, B.S., Arizona Cancer Center, Tucson, AZ,
USA
"Indomethacin-Induced Alterations in Phospholipid Metabolism of Malignant and
Non-malignant Human Mammary Epithelial Cells Studied by 1H and 13C NMR"
Kristine Glunde, Johns Hopkins University School of Medicine, Baltimore, MD,
USA
|
10:30-10:50 |
Break |
10:50-12:15 |
pH and Lactate
Chair: Marion Stubbs, D.Phil., St. George's Hospital Medical School, London,
England, UK
- 10:50-11:10: "Understanding the Tumor Metabolic Phenotype in
the Genomic Era"
Marion Stubbs, D.Phil., St. George's Hospital Medical School, London, England,
UK
- 11:10-11:30: "Comparison of extracellular pH and lactate maps
obtained in in vivo rat brain gliomas by proton spectroscopic imaging"
Chantal R�my, Ph.D., Universit� Joseph Fourier, Grenoble, France
- 11:30-11:50: "Microenvironmental pH and Drug Resistance in
Tumors"
Natarajan Raghunand, Ph.D., University of Arizona, Tucson, AZ, USA
- 11:50-12:10: Proffered Papers:
Use of 1H Magnetic Resonance Spectroscopic Imaging in Managing Recurrent Glioma Patients
Undergoing Radiosurgery"
Antoinette A. Chan, University of California, San Francisco, CA, USA
"Measurement of Tumor Glycolysis in In Vivo Using 13C MR Spectroscopy"
Harish Poptani, Ph.D., University of Pennsylvania, Philadelphia, PA, USA
|
12:10-13:30 |
Lunch |
13:30-14:15 |
Negendank Memorial Lecture:
"Clinical MRS: Where and when can it make a difference?"
Speaker: John Kurhanewicz, Ph.D., University of California, San Francisco, CA,
USA |
14:15-14:55 |
Poster Discussions:
- "Assignment of Polyunsaturated Lipids in the BT4C Gliomas
Undergoing Gene Therapy-Induced Programmed Cell Death by 1H NMR Spectroscopy"
Julian L. Griffin, Ph.D., Imperial College of Science, Technology &
Medicine, London, England, UK
- "Correcting the Arterial Input Function for T2* Shortening in
Perfusion and Permeability Studies of Abdominal and Thoracic Metasteses at 3.0 Tesla"
Cedric de Bazelaire, M.D., Beth Israel Deaconess Medical Center, Boston, MA,
USA
- "Integrating In Vivo MRI and MRSI Data for
Non-Invasive Classification of Gliomas"
Xiaojuan Li, M.S., University of California, San Francisco, CA, USA
- "Differentiation of Metasteses from High-Grade Gliomas using
Short Echo Time 1H MR Spectroscopy"
Kirstie S. Opstad, B.Sc., St. George's Hospital Medical School, London,
England, UK
- "Intratumor and Intertumor Heterogeneity in Contrast Agent
Kinetics as Assesses by Functional MRI - Initial Results with Implications for
Metastasis"
Arvind P. Pathak, Ph.D., Johns Hopkins University School of Medicine,
Baltimore, MD, USA
|
14:55-16:10 |
Poster Session 2: Functional and Molecular Assessment of Cancer |
16:10-17:00 |
Free time |
17:00-18:00 |
Prospects
of High Magnetic Fields in Cancer
Chair: Jeffry R. Alger, Ph.D., UCLA School of Medicine, Los Angeles, CA, USA
Intro lectures, followed by roundtable discussion
- 17:00-17:20: "Advantages of High Magnetic Fields in
Cancer"
Michael Garwood, Ph.D., University of Minnesota, Minneapolis, MN, USA
- 17:20-17:40: "Disadvantages of High Magnetic Fields in
Cancer"
Truman R. Brown, Ph.D., Columbia University, NY, New York, USA
- 17:40-18:00: Roundtable discussion
|
18:00-23:00 |
Private
Dinner and Reception |
Monday, 21 October |
07:00-09:00 |
Breakfast |
09:00-09:40 |
Regulatory issues related to the introduction of new MRI agents
Michael V. Knopp, M.D., The Ohio State University, Columbus, OH, USA |
09:40-12:00 |
Cancer MR: Current role and future directions of Cancer MR:
Generate white paper
Chair: Jeffrey L. Evelhoch, Ph.D., Wayne State University, Detroit, MI, USA
The purpose of this session is to reach a consensus on what the ISMRM MR of Cancer Study
Group considers to be areas of MR research which, over the next few years, are most likely
to advance our understanding of the fundamental biology of cancer and to advance the use
of MR in the diagnosis and management of patients with cancer. This consensus will be
briefly summarized in a paper (a so-called "white paper") that will be
appropriate for distribution to funding agencies and administrators to make clear the
Study Group's position on this topic and, hopefully, encourage them to support research in
these areas. |
|
End of Workshop |
12:00-13:30 |
Lunch |
|
|